Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Pareto Securities in its capacity as Sole Manager and Bookrunner in connection with a directed share issue
Mandate

Vinge has advised Pareto Securities in its capacity as Sole Manager and Bookrunner in connection with a directed share issue

November 12, 2020 Capital Markets and Public M&A

Vinge has advised Pareto Securities in its capacity as Sole Manager and Bookrunner in connection with a directed share issue in the pharmaceutical company Xbrane Bipharma, whereby Xbrane Biopharma receives gross proceeds of approximately SEK 200 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue was, inter alia, to carry out a capital raise in a timely and cost-effective manner, further diversifying and strengthening Xbrane Biopharma´s shareholder base, as well as finance the continued development of Xbrane Biopharma´s product portfolio, including finalization of development and the regulatory process regarding Xlucane.

Vinge’s team has consisted of Jesper Schönbeck, Linnéa Sellström, Anders Sundin Lundberg and Lisa Malmborg.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025